Importantly, MK2-depleted mice are viable [47], in contrast to Chk1 and p38MAPK−/− mice [148], suggesting that MK2 inhibition could target cancer cells the same way as Chk1 and p38MAPK inhibitors but with fewer side-effects. Here, CHEK1 is linked to cancer.